112) Moscarella, E., et al., Digital dermoscopy monitoring in patients with multiple nevi: How many lesions should we monitor per patient? J Am Acad Dermatol, 2015. 73(1): p. 168-70.
113) Puig, S. and J. Malvehy, Monitoring patients with multiple nevi. Dermatol Clin, 2013. 31(4): p. 565-77, viii.
114) Berk-Krauss, J., D. Polsky, and J.A. Stein, Mole Mapping for Management of Pigmented Skin Lesions. Dermatol Clin, 2017. 35(4): p. 439-445. Truong, A., et al., Reduction in nevus biopsies in patients monitored by total body photography. J Am Acad Dermatol, 2016. 75(1): p. 135-143.e5
115) Ferrone, C.R. Clinicopathological features of and risk factors for multiple primary melanomas / C.R. Ferrone, L. Ben Porat, K.S. Panageas et al. // JAMA. – 2005. – № 294. – P. 1647–1654. 15. Ferrone, C.
116) 8) Stam-Posthuma, J.J. Multiple primary melanomas / Stam-Posthuma J.J., van Duinen C., Scheffer E. et al. // J Am Acad Dermatol. – 2001. – №44. – P. 22–27.
117) Kang, S. Multiple primary cutaneous melanomas / S. Kang, R.L. Barnhill, M.C. Mihm // Cancer. – 1992. – №70. – P. 1911–1916
118) Marghoob, A.A. Basal cell and squamous cell carcinomas are important riskfactors for cutaneous malignant melanoma. Screening implications / A.A. Marghoob, J. Slade, T.G. Salopek et al. // Cancer. 1995 – №75. – Suppl. 2. – P. 707–71
119) Pielop, J.A. Mycosis fungoides associated with malignant melanoma and dysplastic nevus syndrome / J.A. Pielop, I. Brownell, M. Duvic // Int J Dermatol. – 2003. – №42 – P.116–122.
120) Ransohoff, K. J. Familial skin cancer syndromes increased melanoma risk /K. J. Ransohoff, P. D. Jaju, J. Y. Tang et al. // Journal of the American Academy of Dermatology. – 2016. – Vol. 74 – №3 – P. 423–434.
121) 13) Read, J. Melanoma genetics / J. Read, K. A. W. Wadt, N. K. Hayward // Journal of Medical Genetics. – 2015. – №53. – P. 1–14.
122) Greene, M.H. High risk of malignant melanoma in melanoma-prone families with dysplastic nevi / M.H. Greene, W.H. Clark Jr., M.A. Tucker et al. // Ann Intern Med. – 1985. – №102. – P. 458–465/
123) Fusaro, R.M. The FAMMM syndrome: epidemiology and surveillance strategies / R.M. Fusaro, H.T. Lynch // Cancer Invest. – 2000. – № 18 – P. 670–680
124) Psaty, E.L. Defining the patient at high risk for melanoma / E.L. Psaty, A. Scope, A.C. Halpern et al. // Int J Dermatol. – 2010 Apr. – Vol.49. – №4 – 362-76.
125) Cust, A.E.. Sunbed use during adolescence and early adulthood is associated with increased risk of early-onset melanoma / A.E. Cust, B.K. Armstrong, C. Goumas et al. // Int J Cancer. – 2011. – №128. – P. 2425-35
126) Stern, R.S. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study / R.S. Stern, K.T. Nichols, L.H. Vakeva // N Engl J Med. – 1997. – №336. – P. 1041–1045
127) Sanlorenzo, M. The Risk of Melanoma in Pilots and Cabin Crew: UV Measurements in Flying Airplanes / M. Sanlorenzo, I. Vujic, C. Posch et al. // JAMA Dermatol. – 2015 Apr 1. – Vol. 151. – №4). – 450-2
128) Gandini S, Sera F, Cattaruzza MS, Pasquini P, Zanetti R, Masini C, Boyle P, Melchi CF. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer. 2005 Sep;41(14):2040-59. doi: 10.1016/j.ejca.2005.03.034. PMID: 16125929/
129) Elwood JM, Gallagher RP, Worth AJ, Wood WS, Pearson JC. Etiological differences between subtypes of cutaneous malignant melanoma: Western Canada Melanoma Study. J Natl Cancer Inst. 1987 Jan;78(1):37-44. doi: 10.1093/jnci/78.1.37. PMID: 3467128.
130) Argenziano G, Giacomel J, Zalaudek I, Apalla Z, Blum A, De Simone P, Lallas A, Longo C, Moscarella E, Tiodorovic-Zivkovic D, Tiodorovic J, Jovanovic DL, Kittler H. Twenty nevi on the arms: a simple rule to identify patients younger than 50 years of age at higher risk for melanoma. Eur J Cancer Prev. 2014 Sep;23(5):458-63..
131) Diagnosis and treatment of early melanoma. NIH Consensus Development Conference. January 27-29, 1992. Consens Statement. 1992 Jan 27-29;10(1):1-25. PMID: 1515516.
132) Moscarella E, Piccolo V, Argenziano G, Lallas A, Longo C, Castagnetti F, Pizzigoni S, Zalaudek I. Problematic lesions in children. Dermatol Clin. 2013 Oct;31(4):535-47, vii
133) Alikhan A, Ibrahimi OA, Eisen DB. Congenital melanocytic nevi: where are we now? Part I. Clinical presentation, epidemiology, pathogenesis, histology, malignant transformation, and neurocutaneous melanosis. J Am Acad Dermatol. 2012 Oct;67(4):495.e1-17; quiz 512-4.
134) E. Bonifazi, M. Bilancia, A. Berloco et al. Malignant melanoma in children aged 0-12. Review of 289 cases of the literature. Eur J Pediatr Dermatol. 2001; 11: 157–75
135) Krengel S, Hauschild A, Schäfer T. Melanoma risk in congenital melanocytic naevi: a systematic review. Br J Dermatol. 2006 Jul;155(1):1-8
136) Kadonaga JN, Frieden IJ. Neurocutaneous melanosis: definition and review of the literature. J Am Acad Dermatol. 1991 May;24(5 Pt 1):747-55
137) Zalaudek I, Lallas A, Longo C, Moscarella E, Tiodorovic-Zivkovic D, Ricci C, Albertini G, Argenziano G. Problematic lesions in the elderly. Dermatol Clin. 2013 Oct;31(4):549-64, vii-viii.